Find out what to expect when you start treatment with HUMIRA for moderate to severely active psoriatic arthritis
With HUMIRA some people may expect an improvement in joint symptoms in as little as two weeks, and for some people joint symptom improvements may take three months or longer.1
Start out on the right path by learning how to take HUMIRA correctly
The usual recommended dose for adults with psoriatic arthritis is a 40mg injection once every two weeks. Your rheumatologist or dermatologist will decide what dosage of HUMIRA you require and how often you need to administer the injection. Only inject as prescribed by them.
Humira is given by injection just under the skin. HUMIRA is available in either a pre-filled single use syringe, or pre-filled single use auto-injector pen and both come pre-loaded with the exact dose of medicine inside, so it comes ready to inject and you can do it by yourself. Your rheumatologist, dermatologist or nurse will be able to help you and be with you for your first injection however before long you will be able to do it by yourself, or if not, it can be given by another healthcare professional or a family member or friend after they have been trained to give injections. Also, for people on HUMIRA in New Zealand you can join the AbbVie Care support programme with access to a nurse to help you.
Watch these short videos to get a better understanding of how to inject HUMIRA.
Storage and travelling with HUMIRA
Keep HUMIRA in the outer carton until it is time to use it. HUMIRA must be kept in the refrigerator (+2° C to +8° C) but don’t allow it to freeze. If you are travelling the HUMIRA pre-filled pen or pre-filled syringe may be stored at room temperature (below +25° C) for a maximum period of 14 days, but it must be protected from light. Once removed from the refrigerator for room temperature storage, the syringe or pen must be used within 14 days or discarded even if it is returned to the refrigerator. If additional syringes or pens are being carried, they should be refrigerated (kept between 2°C–8°C).
Join AbbVie Care to receive an ice pack and order a travel wallet through www.abbviecare.co.nz or call 0800 848 243.
When planning to travel overseas it is important that you:
- talk to your doctor about travelling with HUMIRA
- carry a letter from your doctor detailing what HUMIRA is, how much you will be taking, and stating that it is for your own personal use
- leave HUMIRA in its original packaging so it is clearly labeled with your name and dosage instructions (if you are taking HUMIRA pens/syringes with you)
AbbVie Care Support Programme helps take care of you
AbbVie Care is available to you when you are taking HUMIRA. Support from AbbVie Care is designed to complement the care you receive from your specialist and clinic nurse.
AbbVie Care provides personalised support to meet each person’s needs. The aim is by working together people can achieve better outcomes with their health and quality of life.
It’s easy to ENROL
JOIN AbbVie Care to get the best out of your HUMIRA treatment
• Go online to www.abbviecare.co.nz
• Call 0800 848 243
How AbbVie Care supports you:
AbbVie Care Nurse Support
– Home visits or phone calls to help with injecting^
– Scheduled phone calls to provide information and support
– An 0800 number to call when you have a question
Sharps Disposal Programme
– Delivery of sharps container to safely dispose of your HUMIRA pens and syringes
– Access to pharmacy disposal of your sharps container
– Designed to make travelling with HUMIRA safer and easier
– Information on all you need to know to get the best out of AbbVie Care
– Ice pack to assist with injecting
# All experiences, possible outcomes or improvements are hypothetical and based on significant Quality Of Life (QOL) improvements as measured in the listed clinical studies. Use of these references does not imply endorsement or approval by any individual or the authors.
^Home visits do not cover all of New Zealand. Your AbbVie Care Nurse will be able to discuss this with you when you join AbbVie Care.
- Mease P. J., et al. Arthritis Rheum. 2005;52:3279–89
- Gladman D, et al. J Rheumatol 2010;37:1898-1906
- Gladman D, et al. Arthritis Rheum. 2007;56:476-88
- Mease, P. J. et al. Ann Rheum Diss, 2009;68(5), 702–09.
NZ-HUM-0120 TAPS PP9594 Prepared May 2017